Anti-miRNA Oligonucleotide Therapy for Chondrosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Nanotechnology

Background:

• Chondrosarcoma is an aggressive bone cancer with poor prognosis and no effective systemic treatments.
• miR-181a, an oncomiR, is overexpressed in chondrosarcoma, promoting tumor progression by downregulating Regulator of G-protein signaling 16 (RGS16).
• miR-181a-mediated RGS16 inhibition enhances signaling pathways (CXCR4) that drive angiogenesis and metastasis via increased MMP1 and VEGF expression.

Purpose of the Study:

• To investigate the efficacy of systemic delivery of anti-miRNA oligonucleotides (AMO) against miR-181a using a nanopiece (NP) delivery platform for chondrosarcoma treatment.
• To evaluate the impact of this systemic AMO delivery on miR-181a expression, RGS16 restoration, and downstream oncogenic pathways in vivo.

Main Methods:

• Development and utilization of nanopiece (NP) delivery platforms for anti-miR-181a oligonucleotides.
• In vitro and in vivo transfection of chondrosarcoma cells with NPs carrying anti-miR-181a.
• Assessment of miR-181a expression, RGS16 levels, VEGF and MMP1 expression, MMP activity, tumor volume, and survival in nude mice bearing chondrosarcoma xenografts following systemic NP treatment.

Main Results:

• Systemic delivery of NPs carrying anti-miR-181a effectively transfected chondrosarcoma cells both in vitro and in vivo.
• Treatment restored RGS16 expression and decreased expression of VEGF and MMP1, along with reduced MMP activity.
• Significant reduction in tumor volume (32% by day 38) and prolonged survival (from 23% to 45%) were observed with systemic AMO delivery.

Conclusions:

• Systemic delivery of anti-miRNA oligonucleotides targeting miR-181a via a nanopiece platform demonstrates significant therapeutic potential for chondrosarcoma.
• This approach offers a promising novel strategy for managing this aggressive bone malignancy, addressing the unmet need for effective systemic treatments.